Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Dec 03, 2018
In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) This was the first prospective study to evaluate the effect of oral leucovorin in preventing or reducing
Nov 30, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data
Nov 13, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 13, 2018-- Spectrum Pharmaceuticals Inc. , (NASDAQ: SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca , MD, FACP to
Nov 08, 2018
Poziotinib interim data from the MD Anderson Phase 2 study presented in Q3 demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutations in NSCLC patients Spectrum has submitted a request for Breakthrough Therapy Designation (BTD) for poziotinib and expects a
Nov 07, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 7, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy
Nov 01, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 1, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with
Oct 23, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the U.S.
Oct 18, 2018
Veteran of the Biopharmaceutical Industry Joins as Company Advances Two Late-stage Oncology Therapies HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 18, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a
Sep 27, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 27, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business
Sep 24, 2018
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Spectrum will host a live webcast today at 4:30 p.m. Eastern/1:30 p.m. Pacific HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 24, 2018-- Spectrum Pharmaceuticals, Inc.
Sep 12, 2018

Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations Phase 2 study now includes four cohorts with each cohort being an independent study with pre-specified statistical hypotheses

Sep 05, 2018

The abstract reported new interim data from the EGFR cohort and, for the first time, the HER2 cohort in the MD Anderson Phase 2 trial In the EGFR cohort, an objective response rate of 58% and a disease control rate of 90% were reported In the HER2 cohort, an objective response rate of 50% and a

Aug 30, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 30, 2018-- Spectrum Pharmaceuticals, Inc.  (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business

Aug 09, 2018

An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent

Aug 02, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 2, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

Jun 29, 2018

ADVANCE, first Phase 3 study, met the non-inferiority of ROLONTIS to pegfilgrastim endpoint in the Duration of Severe Neutropenia (DSN) across all 4 cycles (all p

Jun 25, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 25, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday,

May 30, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy

May 16, 2018

Primary endpoint of non-inferiority of ROLONTIS to pegfilgrastim was met All secondary endpoints were met Adverse events were similar between ROLONTIS and pegfilgrastim ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a propriety technology HENDERSON,

May 09, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 9, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy

Displaying 21 - 40 of 781